Adamis Pharmaceuticals announces new commercialization agreement in the US for Symjepi and Zimhi products

Adamis Pharmaceuticals Corporation announced it is reacquiring from Sandoz Inc. the rights to its Symjepi(epinephrine) Injection 0.3mg, Symjepi (epinephrine) Injection 0.15mg products currently marketed and available in the United States. Adamis has simultaneously entered into an exclusive distribution and commercialization agreement with US WorldMeds, LLC for the United States commercial rights for the Symjepi products, as well as its Zimhi (naloxone HCI Injection, USP) 5mg/0.5mL product candidate.

Adamis and Sandoz have entered into an agreement providing for the mutually agreed return to Adamis of the marketing, promotion, and distribution rights of the Symjepi products, and the termination of the commercialization agreement between Adamis and Sandoz, following a transition period, supported by a transition services agreement that is currently being negotiated. As part of the termination agreement, Sandoz will continue to support the products in the U.S. under the existing commercialization agreement through the end of the transition period to help minimize any potential impact to patients and customers.

Under the terms of the Adamis/US WorldMeds agreement, US WorldMeds obtained U.S. rights to commercialize and distribute the Symjepi products, upon the termination of Sandoz’ commercial rights, and Zimhi, if approved by the FDA, in exchange for an upfront payment and potential regulatory and commercial milestones totaling up to $26 million. Additionally, after deducting the supply price and certain other deductions, including an allocation for US WorldMeds sales and distribution expenses from net sales of the products, Adamis and US WorldMeds will share equally in the net profits, as defined in the agreement.